The goal: eliminate or reduce the potential exposure of personnel or the environment. “Biohazardous materials” are defined as materials of biological origin that have the capacity to produce deleterious effects on humans or animals. These include:

• recombinant DNA molecules
• microorganisms classified in various Risk Groups (RG-1, RG-2, RG-3, or RG-4) and their biological products
• specimens known to (or reasonably expected to) contain human pathogens
• hazardous microorganisms
• combinations of or waste derived from these

This responsibility is described in the IBC Procedure Manual 2019. The UMKC IBC is the IBC-of-record for research at affiliated Kansas City institutions, including Children's Mercy Hospital, Saint Luke's Hospital, and Truman Medical Center. The IBC and its Biosafety Officers (BSOs) are responsible to evaluate and monitor research and teaching at UMKC and the affiliated institutions for biological safety considerations.

Essential Information

UMKC IBC Human Cell Line policy

Changes to Federal Oversight of Human Gene Transfer

August 2018: Requirement Removed

The NIH Office of Science Policy will no longer require review by its Recombinant DNA Advisory Committee (RAC) of proposed HGT protocols or reports.

For details, see the NIH Director's Statement

• UMKC Biosafety Manual
• NIH Guidelines 2019 for Research Involving Recombinant DNA Molecules